Recent Updates
Recently added Catalysts
ANGO Positive Sentiment Score: 70/100

AngioDynamics to Participate in Upcoming Investor Conferences

Tuesday, July 28, 2026 1 min read
Key Takeaway: AngioDynamics, Inc. (NASDAQ: ANGO) has announced its participation in several upcoming investor conferences, including the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. This engagement reflects the company's commitment to connect with investors and stakeholders. The focus on restoring healthy blood flow and expanding cancer treatment options is central to their mission.

Market Sentiment Analysis

POSITIVE FACTORS

  • AngioDynamics is actively engaging with investors.
  • Participation in multiple conferences highlights company growth.
  • Focus on improving patient quality of life is commendable.

Full Press Release Details

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Monday, August 10, 2026 Canaccord Genuity's 4

Frequently Asked Questions

What conferences will AngioDynamics participate in?

AngioDynamics will participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference.

What is the focus of AngioDynamics?

AngioDynamics focuses on restoring healthy blood flow and expanding cancer treatment options.

When is the Needham Virtual Conference scheduled?

The Needham Virtual MedTech & Diagnostics 1x1 Conference is scheduled for August 10, 2026.

What is the ticker symbol for AngioDynamics?

The ticker symbol for AngioDynamics is NASDAQ: ANGO.

Tags: ANGO Viatris Investor Conferences Healthcare AngioDynamics investor conferences medical technology NASDAQ: ANGO patient care
Last updated: Jul 28, 2026

Biotech snapshot

Cash runway
$54M liquidity · $0M/mo burn
Low dilution risk
Lead asset
IP-001Phase 1
Colorectal Cancer →